Corbus Pharmaceuticals Holdings, Inc.
CRBP
$6.68
$0.558.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 171.47% | 25.89% | 64.98% | 61.57% | -56.96% |
| Gross Profit | -171.47% | -25.89% | -64.98% | -61.57% | 56.96% |
| SG&A Expenses | 7.04% | 22.22% | 59.93% | 4.64% | -1.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.50% | 24.75% | 63.42% | 34.18% | -44.37% |
| Operating Income | -105.50% | -24.75% | -63.42% | -34.18% | 44.37% |
| Income Before Tax | -146.09% | -18.80% | -37.10% | -13.81% | 61.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -146.09% | -18.80% | -37.10% | -13.81% | 61.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.09% | -18.80% | -37.10% | -13.81% | 61.12% |
| EBIT | -105.50% | -24.75% | -63.42% | -34.18% | 44.37% |
| EBITDA | -107.94% | -25.26% | -64.47% | -34.95% | 44.66% |
| EPS Basic | -67.60% | 56.85% | 49.52% | 55.96% | 80.44% |
| Normalized Basic EPS | -67.62% | 56.86% | 49.52% | 55.95% | 80.44% |
| EPS Diluted | -67.60% | 56.85% | 49.52% | 55.96% | 80.44% |
| Normalized Diluted EPS | -67.62% | 56.86% | 49.52% | 55.95% | 80.44% |
| Average Basic Shares Outstanding | 46.83% | 175.32% | 171.60% | 158.39% | 98.74% |
| Average Diluted Shares Outstanding | 46.83% | 175.32% | 171.60% | 158.39% | 98.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |